Cheaper macular degeneration treatment may be as effective

Share this article:
The cancer drug Avastin could be as effective as the more expensive Lucentis at improving the vision of seniors with macular degeneration, according to a report from The New York Times.

Lucentis has been approved to treat the eye disease, while physicians have used Avastin as an off-label drug. They say the latter appears to work as well as Lucentis, with the difference coming down to cost: Lucentis costs $2,000 per injection into the eye, while Avastin costs $50.

The National Eye Institute sponsored a randomized trial involving 1,200 patients to compare the two drugs, and the results will be revealed this Sunday at the Association for Research in Vision and Ophthalmology in Fort Lauderdale, FL. While the findings are being kept secret, two people familiar with the results told the New York Times that improved vision resulted from either drug. Patients in the study are being followed for a second year.

The results could mean costs savings for Medicare. In 2008, Medicare paid $20 million for 480,000 Avastin injections for treatment of the eye disease, compared with $537 million for 337,000 Lucentis injections, according to a University of Miami study.

 

Share this article:

More in News

Post-acute standardized assessment bill passes House

Post-acute standardized assessment bill passes House

A bill that would standardize data in post-acute settings moved closer to reality after a House of Representatives voice vote in its favor Tuesday. The House's approval of the Improving ...

ACA hasn't created more part-time workers, analysis says

Despite fears to the contrary, there's no evidence that the Affordable Care Act increased part-time work before 2014, according to a new analysis.

Also in the News for Sept. 18, 2014

Arkansas' charity protection statute could protect nursing home in lawsuit... Institute of Medicine releases end-of-life report ...Congressional roundtable group says Medicare telehealth rules need to be updated